Skip to main content
Premium Trial:

Request an Annual Quote

CollabRx, GeneInsight Collaborate on Sequencing Data

NEW YORK (GenomeWeb News) – CollabRx and GeneInsight today announced a joint initiative to make CollabRx's medical and scientific content accessible through GeneInsight's knowledge management platform.

The combined offering, the two companies said, will result in a medical informatics solution that supports genetic sequencing, interpretation, and reporting in the clinical laboratory. The offering will initially focus on cancer.

The analysis and interpretation of sequencing data is one of the greatest challenges facing clinicians, CollabRx and GeneInsight said. Their combined offering will allow clinical laboratories to catalog genetic variants from sequencing-based tests and link them with CollabRx's curated knowledge on available drugs and clinical trials.

The results will then be "streamlined through GeneInsight's networked infrastructure," so that clinical labs can update physicians on the most recent knowledge in order to better manage patient care.

"Our partnership with GeneInsight goes a long way toward enabling a truly integrated clinical laboratory workflow," Thomas Mika, chairman, president, and CEO of CollabRx, said in a statement.

The deal is the most recent in a string of transactions the San Francisco-based data analytics company has announced recently, following a partnership with Sengenics in cancer diagnostics; a deal with OncoDNA for the development of cancer mutation panels; and a distribution agreement with Projects In Knowledge.

Boston-based GeneInsight is a wholly owned bioinformatics subsidiary of integrated health system Partners Healthcare.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.